Market News & Trends
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients With Intrinsic Driver & Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
Black Diamond Therapeutics, Inc. recently announced the first patients dosed in mutation matched expansion cohorts of non-small cell lung cancer (NSCLC) in the ongoing Phase…
Immatics & Moderna Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Immatics, NV, and Moderna, Inc. recently announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet….
Verona Pharma Announces FDA Has Accepted NDA Filing for Ensifentrine for the Maintenance Treatment of COPD
Verona Pharma plc recently announced the US FDA has accepted for review the company’s New Drug Application (NDA) seeking approval of ensifentrine for the maintenance…
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for Long-Acting Parathyroid Hormone Peptide Prodrug in Healthy Adults
MBX Biosciences, Inc. recently announced positive results from the multiple ascending dose (MAD) portion of the Phase 1 trial of MBX 2109, the company’s long-acting parathyroid…
Shape(TX) Collaborates With Otsuka to Develop Novel AAV Gene Therapies for Ocular Diseases
Shape(TX) and Otsuka Pharmaceutical Co., Ltd. recently announced a multi-target collaboration to develop intravitreally delivered adeno-associated viruses (AAVs) for ocular….
The Evolving Role of a Contract Development & Manufacturing Organization
The meaning of a Contract Development and Manufacturing Organization (CDMO) is not the same as it was a decade ago. Customers today are seeking….
Valneva & Pfizer Report Positive Pediatric & Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. recently announced positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, when given….
Myricx Enters Antibody License Agreement With Biocytogen
Myricx Bio recently announced an antibody license agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd, a global biotech company focusing on the….
Avextra Signs Distribution Agreements With Pharmaceutical Partners & Commences Exports of Cannabis-Based Medicines to Switzerland & Austria
Avextra AG recently announced the signing of three long-term supply and distribution agreements. Avextra has signed distribution agreements with two leading Swiss pharmaceutical partners and…
Artelo Biosciences Completes Positive Pre-IND Meeting With FDA
Artelo Biosciences, Inc. recently announced it has completed a pre-IND meeting with the US FDA regarding the manufacturing, preclinical, and clinical development plan for ART26.12.…
Antion Announces Granting of Key Technology Patent in the United States
Novel patent solidifies Antion’s position as an industry leader in multiplex engineering of cell and gene therapies….
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment With Tegoprubart Promotes Kidney & Islet Allograft Survival & Function in Nonhuman Primates
Eledon Pharmaceuticals, Inc. recently announced the publication of a study evaluating tegoprubart as an immunomodulatory monotherapy in nonhuman primate kidney and islet allotransplants. The study,…
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement With Giiant Pharma for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
Palisade Bio, Inc. recently announced it has entered into a licensing agreement with Giiant Pharma, Inc., providing the company with the exclusive worldwide rights to develop, manufacture, and commercialize….
Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial in Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics, Inc. recently announced a positive outcome of the prespecified interim futility analysis for the ASCEND trial, a Phase 2b study evaluating LSTA1, Lisata’s…
Recipharm Partners With Ahead Therapeutics to Develop Rare Autoimmune Disease Therapy
Recipharm is partnering with Ahead Therapeutics to develop a ground-breaking treatment for a rare autoimmune disease, myasthenia gravis. Ahead Therapeutics is a Spanish start-up biotech…
Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer
Nykode Therapeutics ASA recently announced FDA approval of its investigational new drug (IND) application for the Phase 2 clinical trial. The trial is designed to…
Zenas BioPharma Announces Strategic License & Collaboration Agreement With Bristol Myers Squibb
Collaboration furthers Zenas’ vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb’s long-standing expertise in immune-mediated diseases….
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
Recursion recently announced it has completed the Phase 1 study for REC-3964 in healthy volunteers. The study achieved its primary objectives of assessing the safety,…
SomaLogic Expands Agreement With Novo Nordisk to 2025
Novo Nordisk will extend its use of SomaLogic’s innovative proteomics technologies for research in cardiometabolic and other diseases….
Optibrium Acquires BioPharmics, Expanding its 3D Drug Design & Visualization Offering
Optibrium recently announced the acquisition of BioPharmics LLC, expanding its 3D drug design and modelling offering. Bringing decades of experience in computational chemistry and biology…..
